Angiogenesis

Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations

Retrieved on: 
금요일, 2월 10, 2023
OCT, MOA, AMD, Patient, GA, HIV disease progression rates, University of California, Irvine Medical Center, Oxidative stress, University, Angiogenesis, Visual acuity, Macular degeneration, Bascom Palmer Eye Institute, Disease, Geographic atrophy, Pharmaceutical industry, Ophthalmology

SAN JUAN CAPISTRANO, Calif., Feb. 10, 2023 /PRNewswire/ -- Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced the presentation of key data supporting dry AMD pipeline candidates, including the company's risuteganib (Luminate®), this morning at Bascom Palmer Eye Institute's 20th annual Angiogenesis, Exudation and Degeneration meeting, being held virtually February 10-11, 2023.1

Key Points: 
  • The only two pipeline candidates that have shown best corrected visual acuity (BCVA) gains in intermediate dry AMD are mitochondrial stabilizing drugs, including risuteganib.
  • "Existing data suggest that restoration of functional vision is achievable in Dry AMD patients with more anatomical integrity, or less disease progression, using these mitochondrial stabilizing drug candidates," explained Dr. Kuppermann.
  • "This underscores the potential for early treatment of Dry AMD, with the right therapeutic agent, to reverse vision loss."
  • "Treatments for Dry AMD remain a significant unmet need, and we believe that, given the evidence and considerations put forth by Dr. Kuppermann, risuteganib has tremendous potential to help address that need."

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

Retrieved on: 
월요일, 2월 6, 2023
Angiogenesis, Safety, Conference, CGMP, Pharmaceutical industry

ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023.

Key Points: 
  • ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023.
  • New data will be presented from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314 delivered subretinally using cGMP material produced by the REGENXBIO NAVXpress™ platform process to support future commercialization.
  • The presentations will be as follows:
    Presentation Title: Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase II Pharmacodynamic Study

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Retrieved on: 
토요일, 2월 11, 2023
Safety, VEGF, Șaeș, Conference call, Eye, Injection, Endophthalmitis, Clinical research, Interim, Conference, Diabetic retinopathy, MBA, TKI, SAE, Maintenance, Angiogenesis, Axitinib, IOP, Treatment, FDA, American Academy, Visual acuity, Month, Wet, Clinical trial, Arm, Retinal detachment, Patient, AMD, Retinal vasculitis, Webcast, Diabetes, Pharmaceutical industry, MD, Retina

BEDFORD, Mass., Feb. 11, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 10-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy and other retinal diseases. The data is being presented this morning at 8:00 am ET at the Angiogenesis, Exudation, and Degeneration 2023 Virtual Meeting by Andrew A. Moshfeghi, MD, MBA. The presentation can be accessed by visiting the scientific and medical presentations tab of the investor section of the Company’s website at investors.ocutx.com.

Key Points: 
  • Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy and other retinal diseases.
  • These results demonstrated maintenance of controlled wet AMD subjects for up to 10 months with a single administration of OTX-TKI.
  • Phase 1 clinical trial who previously required many injections is very exciting,” said Arshad M. Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates.
  • “The data from the current trial is promising as 73% of the treated subjects were rescue-free up to Month 10.

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

Retrieved on: 
금요일, 1월 6, 2023
Clinical trial, Severe cognitive impairment, Eye, Arm, Pain, Allergic conjunctivitis, BVCA, Bimatoprost, AAO, Glaucoma, Type 2 diabetes, Inflammation, Angiogenesis, Risk, Growth, Patient, DR, American Academy, Ophthalmology, AMD, Axitinib, Diabetic retinopathy, Safety, ASC, Protocol, FDA, Ocular hypertension, Visual acuity, Diagnosis, Intraocular pressure, Trial of the century, Video game, Renewable energy, Pharmaceutical industry, Dentistry, Medical device

“2022 marked a year in which Ocular made good progress against its corporate mission of becoming a mid-tier strategic within ophthalmology,” said Antony Mattessich, President and CEO.

Key Points: 
  • “2022 marked a year in which Ocular made good progress against its corporate mission of becoming a mid-tier strategic within ophthalmology,” said Antony Mattessich, President and CEO.
  • With that in mind, we initiated a Phase 1 clinical trial in diabetic retinopathy in December 2022 and anticipate presenting interim data from this trial in 2023.
  • On a preliminary basis, the Company had estimated cash and cash equivalents of $102.3 million as of December 31, 2022.
  • The Company plans to post an updated corporate presentation that can be found in the ‘Investors’ section of its corporate website on Monday, January 9, 2023.

Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)

Retrieved on: 
목요일, 1월 5, 2023
Acta Ophthalmologica, Clinical research, Dexamethasone, CST, Diabetic retinopathy, Angiogenesis, Patient, Macular edema, Keck School of Medicine of USC, Physician, Safety, University, University of Nevada, Reno School of Medicine, University of Nevada, Reno, Conference, University of Southern California, Visual acuity, Quality of life, SD, DME, Pharmaceutical industry, Ophthalmology, Massilia oculi

At the end of 2021, Oculis launched its 2 stage Phase 3 DIAMOND study, a double-masked, randomized, vehicle-controlled, multi-center, multi-country study of OCS-01 in patients with DME.

Key Points: 
  • At the end of 2021, Oculis launched its 2 stage Phase 3 DIAMOND study, a double-masked, randomized, vehicle-controlled, multi-center, multi-country study of OCS-01 in patients with DME.
  • Several vision and anatomical secondary endpoints are also planned, including the mean change in macular thickness (CST, central subfield thickness) measured by SD-OCT (spectral domain optical coherence tomography) from baseline.
  • Riad Sherif, M.D., CEO of Oculis, said: "I am delighted Oculis has completed patient enrollment for stage 1 of our DIAMOND study.
  • At present, OCS-01, developed using the proprietary Optireach® technology, seems to be one of the most promising drug candidates in Phase 3.

AIM Biotech Launches organiX, a New System to Model Human Disease by Combining Organoids, Perfusable Vasculature and Immune-Competence

Retrieved on: 
월요일, 10월 3, 2022
Biotechnology, Patient, Drug discovery, Physiology, Disease, Organoid, Angiogenesis, Medical imaging, Telescopic sight, Pharmaceutical industry

Boston, Massachusetts and Singapore, Singapore--(Newsfile Corp. - October 3, 2022) - AIM Biotech announced the launch of the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids and tumor biopsies.

Key Points: 
  • Boston, Massachusetts and Singapore, Singapore--(Newsfile Corp. - October 3, 2022) - AIM Biotech announced the launch of the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids and tumor biopsies.
  • Adding vascularization and immune cells to a disease model creates a more defined and tunable microenvironment to more closely emulate the complexity of human physiology.
  • As a result, labs can now generate a deeper understanding of human disease, design superior therapies, more accurately predict clinical success of investigational therapies, and better tailor treatments to patients.
  • AIM Biotech is a biotechnology company at the forefront of transforming drug discovery into a more targeted, predictable and less expensive endeavor.

Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer

Retrieved on: 
화요일, 9월 13, 2022
Safety, NYSE, FDA, Disease, ANN, Talazoparib, Melanoma, Patient, Stata, Cancer, Axitinib, PFE, RNA, MRD, DNA, Neoplasm, Angiogenesis, Pharmaceutical industry, Medical imaging, Stratum, Pfizer

ANN ARBOR, Mich., Sept. 13, 2022 /PRNewswire/ -- Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial. Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. Pfizer will provide Braftovi® (encorafenib), Mektovi® (binimetinib), and Lorbrena® (lorlatinib) for up to six new cohorts of patients with early-stage lung, melanoma, colorectal, and other cancers who have evidence of micrometastatic disease after initial treatment. Pfizer is already providing Strata with Braftovi® (encorafenib), Mektovi® (binimetinib), Lorbrena® (lorlatinib), Talzenna® (talazoparib), and Inlyta (axitinib) for evaluation in four late-stage cohorts of the Strata PATH trial.

Key Points: 
  • a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial.
  • Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.
  • Pfizer is already providing Strata with Braftovi (encorafenib), Mektovi(binimetinib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Inlyta (axitinib) for evaluation in four late-stage cohorts of the Strata PATH trial.
  • Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer.

Cervical Cancer Therapeutics Market Research Report 2022: Epidemiology & Pipeline Analysis 2022-2027 - 282+ Trials in Various Phases of Development - ResearchAndMarkets.com

Retrieved on: 
화요일, 7월 26, 2022
Pharmaceutical, Health, Oncology, Knowledge, Diagnosis, Awareness, Human papillomavirus infection, National Comprehensive Cancer Network, Chemoradiotherapy, Food, Angiogenesis, HPV, Bevacizumab, Woman, Adenocarcinoma, Research, Ageing, Histology, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Therapy, Immune system, Classification, Cervical cancer, Age, Profile, CAGR, Squamous cell carcinoma, Clinical trial, PD-L1, FDA, Disease management, Company, Patient, Prevalence, PAP, Growth, HIV, Birth control, Pharmaceutical industry, Vaccine, Medical device, Pembrolizumab, Disease, Epidemiology, Phase

The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development.
  • Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti-P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer.
  • The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer.

Global Colorectal Cancer Drugs Industry Analysis, 2022-2026, Featuring Merck & Co, Roche, Sanofi, Amgen, and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
수요일, 7월 13, 2022
General Health, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, Angiogenesis, Bevacizumab, Apoptosis, Pembrolizumab, American Cancer Society, Demography, ACS, Panitumumab, Patient, Inflammation, Large intestine, COVID-19, Colorectal cancer, Bladder cancer, Cancer, Cardiovascular disease, Celgene, Tobacco, Geography, Toxicity, CAGR, Forecasting, Immune system, Growth, Obesity, Cetuximab, Medical device, Pharmaceutical industry, Oil, Retail

The "Colorectal Cancer Drugs Global Market Report 2022, Type, Distribution Channels, Class" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Colorectal Cancer Drugs Global Market Report 2022, Type, Distribution Channels, Class" report has been added to ResearchAndMarkets.com's offering.
  • The global colorectal cancer drugs market is expected to grow from $12.77 billion in 2021 to $13.6 billion in 2022 at a compound annual growth rate (CAGR) of 6.5%.
  • North America was the largest region in the colorectal cancer drugs market in 2021.
  • The increase in number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance

Retrieved on: 
수요일, 6월 1, 2022
Research, Diabetes, Clinical Trials, Hispanic, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Yee, Exercise, Triple-negative breast cancer, MSK, Breast cancer, Hormone, TNBC, Research, Leptin, Diabetes, Survival, Metastasis, PI3K, Obesity, Cancer, METAP2, Growth hormone, Angiogenesis, Therapy, Insulin resistance, Â, Breast, Hyperinsulinemia, Patient, Glycated hemoglobin, Insulin, Trial of the century, T2D, Oncology, Growth factor, Lipid, Diet, MD, Overalls, Blood, Drug development, Prediabetes, Adiponectin, Neoplasm, Pharmaceutical industry, Medical device, Medical imaging

SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai).

Key Points: 
  • SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai).
  • Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type 2 diabetes and pre-diabetes).
  • The clinical research study is being conducted in collaboration with New Yorks Memorial Sloan Kettering Cancer Center (MSK).
  • The aim of this research study is to explore the impact of targeting insulin and improving insulin resistance in combination with standard-of-care therapy on patients treatment response and outcomes.